Literature DB >> 24652535

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Cheryl A Sherman-Baust1, Elisabetta Kuhn, Blanca L Valle, Ie-Ming Shih, Robert J Kurman, Tian-Li Wang, Tomokazu Amano, Minoru S H Ko, Ichiro Miyoshi, Yoshihiko Araki, Elin Lehrmann, Yongqing Zhang, Kevin G Becker, Patrice J Morin.   

Abstract

Recent evidence suggests that ovarian high-grade serous carcinoma (HGSC) originates from the epithelium of the fallopian tube. However, most mouse models are based on the previous prevailing view that ovarian cancer develops from the transformation of the ovarian surface epithelium. Here, we report the extensive histological and molecular characterization of the mogp-TAg transgenic mouse, which expresses the SV40 large T-antigen (TAg) under the control of the mouse müllerian-specific Ovgp-1 promoter. Histological analysis of the fallopian tubes of mogp-TAg mice identified a variety of neoplastic lesions analogous to those described as precursors to ovarian HGSC. We identified areas of normal-appearing p53-positive epithelium that are similar to 'p53 signatures' in the human fallopian tube. More advanced proliferative lesions with nuclear atypia and epithelial stratification were also identified that were morphologically and immunohistochemically reminiscent of human serous tubal intraepithelial carcinoma (STIC), a potential precursor of ovarian HGSC. Beside these non-invasive precursor lesions, we also identified invasive adenocarcinoma in the ovaries of 56% of the mice. Microarray analysis revealed several genes differentially expressed between the fallopian tube of mogp-TAg and wild-type (WT) C57BL/6. One of these genes, Top2a, which encodes topoisomerase IIα, was shown by immunohistochemistry to be concurrently expressed with elevated p53 and was specifically elevated in mouse STICs but not in the surrounding tissues. TOP2A protein was also found elevated in human STICs, low-grade and high-grade serous carcinoma. The mouse model reported here displays a progression from normal tubal epithelium to invasive HGSC in the ovary, and therefore closely simulates the current emerging model of human ovarian HGSC pathogenesis. This mouse therefore has the potential to be a very useful new model for elucidating the mechanisms of serous ovarian tumourigenesis, as well as for developing novel approaches for the prevention, diagnosis and therapy of this disease. Published 2014. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  Top2a; fallopian tube; intraepithelial carcinoma; ovarian cancer; p53; transgenic mouse model

Mesh:

Substances:

Year:  2014        PMID: 24652535      PMCID: PMC4149901          DOI: 10.1002/path.4353

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  46 in total

1.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

2.  ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

Authors:  Jan C Brase; Marcus Schmidt; Thomas Fischbach; Holger Sültmann; Hans Bojar; Heinz Koelbl; Birte Hellwig; Jörg Rahnenführer; Jan G Hengstler; Mathias C Gehrmann
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

3.  A comprehensive analysis of PAX8 expression in human epithelial tumors.

Authors:  Anna R Laury; Ruth Perets; Huiying Piao; Jeffrey F Krane; Justine A Barletta; Christopher French; Lucian R Chirieac; Rosina Lis; Massimo Loda; Jason L Hornick; Ronny Drapkin; Michelle S Hirsch
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

4.  High-grade serous ovarian cancer arises from fallopian tube in a mouse model.

Authors:  Jaeyeon Kim; Donna M Coffey; Chad J Creighton; Zhifeng Yu; Shannon M Hawkins; Martin M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

5.  TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.

Authors:  Elisabetta Kuhn; Robert J Kurman; Russell Vang; Ann Smith Sehdev; Guangming Han; Robert Soslow; Tian-Li Wang; Ie-Ming Shih
Journal:  J Pathol       Date:  2011-12-23       Impact factor: 7.996

6.  Molecular changes in brain aging and Alzheimer's disease are mirrored in experimentally silenced cortical neuron networks.

Authors:  Marc Gleichmann; Yongqing Zhang; William H Wood; Kevin G Becker; Mohamed R Mughal; Michael J Pazin; Henriette van Praag; Tali Kobilo; Alan B Zonderman; Juan C Troncoso; William R Markesbery; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2010-10-13       Impact factor: 4.673

7.  Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.

Authors:  Ann Smith Sehdev; Robert J Kurman; Elisabetta Kuhn; Ie-Ming Shih
Journal:  Mod Pathol       Date:  2010-03-12       Impact factor: 7.842

8.  The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.

Authors:  Julia K Bar; Piotr Grelewski; Leszek Noga; Jerzy Rabczyński; Marian Gryboś; Michał Jeleń
Journal:  Adv Clin Exp Med       Date:  2012 Jan-Feb       Impact factor: 1.727

9.  Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.

Authors:  L K Mullany; H-Y Fan; Z Liu; L D White; A Marshall; P Gunaratne; M L Anderson; C J Creighton; L Xin; M Deavers; K-K Wong; J S Richards
Journal:  Oncogene       Date:  2011-03-21       Impact factor: 9.867

Review 10.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

View more
  65 in total

Review 1.  It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Authors:  Ruth Perets; Ronny Drapkin
Journal:  Cancer Res       Date:  2015-12-15       Impact factor: 12.701

Review 2.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

3.  Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.

Authors:  Jiang-Hua Qiao; De-Chuang Jiao; Zhen-Duo Lu; Sen Yang; Zhen-Zhen Liu
Journal:  Tumour Biol       Date:  2015-04-07

4.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

5.  TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.

Authors:  Lin-Yu Chen; Rui-Lan Huang; Michael Wy Chan; Pearlly S Yan; Tien-Shuo Huang; Ren-Chin Wu; Yohan Suryo Rahmanto; Po-Hsuan Su; Yu-Chun Weng; Jian-Liang Chou; Tai-Kuang Chao; Yu-Chi Wang; Ie-Ming Shih; Hung-Cheng Lai
Journal:  J Pathol       Date:  2019-04-23       Impact factor: 7.996

6.  Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.

Authors:  Monica Bodogai; Kanako Moritoh; Catalina Lee-Chang; Christine M Hollander; Cheryl A Sherman-Baust; Robert P Wersto; Yoshihiko Araki; Ichiro Miyoshi; Li Yang; Giorgio Trinchieri; Arya Biragyn
Journal:  Cancer Res       Date:  2015-07-16       Impact factor: 12.701

Review 7.  Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Authors:  Mark E Sherman; Ronny I Drapkin; Neil S Horowitz; Christopher P Crum; Sue Friedman; Janice S Kwon; Douglas A Levine; Ie-Ming Shih; Donna Shoupe; Elizabeth M Swisher; Joan Walker; Britton Trabert; Mark H Greene; Goli Samimi; Sarah M Temkin; Lori M Minasian
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-24

8.  Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.

Authors:  Meredith L Stone; Katherine B Chiappinelli; Huili Li; Lauren M Murphy; Meghan E Travers; Michael J Topper; Dimitrios Mathios; Michael Lim; Ie-Ming Shih; Tian-Li Wang; Chien-Fu Hung; Vipul Bhargava; Karla R Wiehagen; Glenn S Cowley; Kurtis E Bachman; Reiner Strick; Pamela L Strissel; Stephen B Baylin; Cynthia A Zahnow
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

9.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

10.  PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.

Authors:  Angela Russo; Austin A Czarnecki; Matthew Dean; Dimple A Modi; Daniel D Lantvit; Laura Hardy; Seth Baligod; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.